Cytokinetics director sells 2,933 company shares

CYTOKINETICS INC director Edward M. Kaye, MD sold shares in the company.

Rhea-AI Filing Summary

CYTOKINETICS INC director Edward M. Kaye, MD sold shares in the company. He completed an open-market sale of 2,933 shares of Common Stock at a price of $76.09 per share. After this transaction, he directly holds 10,283 shares of Cytokinetics common stock.

Insights

Equity ownership & governance analyst

Cytokinetics director executed a moderate open-market share sale.

Director Edward M. Kaye, MD sold 2,933 shares of CYTOKINETICS INC Common Stock in an open-market transaction at $76.09 per share. Following the sale, he continues to hold 10,283 shares directly.

The filing shows a net-sell of 2,933 shares, with no derivative exercises, gifts, or tax-withholding events reported. With remaining direct ownership still in place and no additional context such as trading plans disclosed, this appears as a routine governance-level transaction based on available information.

Insider Trade Summary 10b5-1

Net Seller: 2,933 shares

Net Sell 1 txn

Insider Kaye Edward M. MD

Role Director

Sold 2,933 shs ($223K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,933	$76.09	$223K

Holdings After Transaction: Common Stock — 10,283 shares (Direct)

Key Figures

Shares sold: 2,933 shares Sale price: $76.09 per share Shares held after sale: 10,283 shares +2 more

5 metrics

Shares sold 2,933 shares Open-market sale of Common Stock

Sale price $76.09 per share Price received in open-market sale

Shares held after sale 10,283 shares Direct ownership following transaction

Net buy/sell shares -2,933 shares Net-sell direction in transaction summary

Sell transactions count 1 transaction Single open-market sale reported

Key Terms

Common Stock, open-market sale, non-derivative, net-sell

4 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"transaction_type: "non-derivative""

net-sell financial

"netBuySellDirection: "net-sell""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTK director Edward M. Kaye report?

Edward M. Kaye, MD reported selling 2,933 CYTOKINETICS INC shares. The Form 4 shows an open-market sale of Common Stock at $76.09 per share, leaving him with 10,283 shares held directly after the transaction.

At what price did Edward M. Kaye sell CYTOKINETICS (CYTK) shares?

He sold CYTOKINETICS Common Stock at $76.09 per share. The transaction involved 2,933 shares in an open-market sale, as disclosed in the Form 4, and was categorized as a non-derivative sale of common shares.

How many CYTOKINETICS shares does Edward M. Kaye hold after this sale?

After the sale, Edward M. Kaye directly holds 10,283 shares. The Form 4 reports total shares following the transaction at 10,283, reflecting his remaining direct ownership of CYTOKINETICS INC Common Stock after selling 2,933 shares.

Was the CYTK insider transaction an open-market sale or option exercise?

The CYTK insider transaction was an open-market sale of common shares. The Form 4 lists transaction code S, describes an open-market sale of 2,933 shares at $76.09, and shows no derivative exercises or option-related activity in this filing.

Does the CYTK Form 4 show any derivative or option positions for Edward M. Kaye?

The Form 4 does not list any remaining derivative positions. The derivative summary is empty, indicating no derivative transactions or unexercised options are reported in this particular filing for Edward M. Kaye, MD.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 06:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S		2,933	D	$76.09	10,283	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John Faurescu, attorney-in-fact for Dr. Kaye	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)